Wellbeing Digital Sciences Inc. (KONEF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Wellbeing Digital Sciences Inc. (KONEF) trades at $0.00 with AI Score 57/100 (Grade B). Wellbeing Digital Sciences Inc. Market cap: $1,576, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for KONEF: KONEF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates KONEF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
KONEF: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Wellbeing Digital Sciences Inc. (KONEF) Healthcare & Pipeline Overview
Wellbeing Digital Sciences Inc. is a Vancouver-based healthcare company specializing in ketamine-assisted therapy and psychedelic medicines through its North American clinic network. It leverages digital therapeutics and technology-enabled solutions, positioning itself in the evolving mental health and wellness sector amidst increasing demand for accessible care.
What Is the Investment Thesis for KONEF?
Wellbeing Digital Sciences Inc. operates in a rapidly expanding mental health and wellness sector, driven by increasing demand for accessible and innovative treatments, particularly in psychedelic-assisted therapies and digital therapeutics. The company's focus on ketamine-assisted therapy through its North American clinics, coupled with its development of technology-enabled healthcare solutions, positions it to capitalize on this market growth. Potential catalysts include further regulatory approvals for psychedelic medicines, increased market adoption of its digital platforms, and successful expansion of its clinic network. However, the company faces significant financial challenges, evidenced by a negative Return on Equity of -656.3% and a low Gross Margin of 6.6%. With a Market Cap of 2K and a Beta of -7.38, the company's financial stability and growth trajectory require close monitoring. The Free Cash Flow of $0.01B indicates some operational cash generation, but the overall financial profile suggests a high-risk, high-potential investment scenario, heavily reliant on future funding and successful execution within a competitive and evolving regulatory environment.
Based on FMP financials and quantitative analysis
KONEF Key Highlights
- Gross Margin of 6.6% reflects the early-stage operational profitability in its healthcare services.
- Return on Equity (ROE) of -656.3% indicates significant net losses relative to shareholder equity, highlighting financial challenges.
- Free Cash Flow (FCF) of $0.01B suggests a limited capacity for internal funding of operations and growth initiatives.
- Market Capitalization of 2K signifies a very small market valuation, typical for early-stage or micro-cap companies.
- A Beta of -7.38 indicates an inverse and highly volatile relationship with the broader market, suggesting unique, company-specific risk factors.
Who Are KONEF's Competitors?
KONEF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| TEVJF Teva Pharmaceutical Industries Limited | $33.00 | +0.00% | $38.43B | 54 |
| OTSKF Otsuka Holdings Co., Ltd. | $64.00 | -3.03% | $33.67B | 58 |
| TRUMF Terumo Corporation | $13.19 | +1.31% | $19.46B | — |
| SDMHF Sartorius Stedim Biotech S.A. | $205.60 | -4.09% | $20.00B | — |
| JDHIF JD Health International Inc. | $5.85 | +0.00% | $18.66B | 51 |
| HWAIF Healwell AI Inc. | $0.53 | -3.52% | $160.75M | 65 |
| ASSF Assisted 4 Living, Inc. | $1.00 | +0.00% | $45.35M | 63 |
| FTRP Field Trip Health Ltd. | $0.84 | +1.07% | $9.81M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are KONEF's Key Strengths?
- Positioning in the growing mental health and wellness sector with innovative therapies.
- Dual focus on physical clinics and digital therapeutics offers a comprehensive approach.
- Early mover in ketamine-assisted therapy in North America.
- Leveraging technology to enhance accessibility and scalability of mental health services.
- Headquartered in Vancouver, Canada, a hub for wellness innovation.
What Are KONEF's Weaknesses?
- Negative Return on Equity (-656.3%) and low Gross Margin (6.6%) indicate financial instability and operational challenges.
- Very small market capitalization ($0.00B) suggests limited access to capital and market visibility.
- OTC Other tier listing presents challenges related to liquidity, transparency, and investor confidence.
- Reliance on evolving regulatory frameworks for psychedelic medicines.
- Negative Beta (-7.38) indicates high volatility and unique, company-specific risk factors.
What Could Drive KONEF Stock Higher?
- Successful expansion of its North American clinic network, increasing patient reach and revenue generation.
- Regulatory approvals for new psychedelic medicines or expanded indications for existing therapies, opening new market opportunities.
- Increased market adoption and positive clinical outcomes from its digital therapeutics and technology-enabled healthcare solutions.
- Securing significant strategic partnerships or funding rounds to support operational expansion and R&D initiatives.
- Growing public and medical acceptance of ketamine-assisted therapy and other psychedelic treatments for mental health.
What Are the Key Risks for KONEF?
- Financial-distress signal — its Altman Z-Score of -9.86 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant financial instability, as indicated by a negative ROE of -656.3% and low Gross Margin of 6.6%, posing challenges for sustained operations.
- High regulatory uncertainty and evolving legal frameworks surrounding psychedelic medicines, which could impact business operations and growth.
- Risks associated with its OTC Other tier listing, including limited liquidity, transparency, and difficulty in attracting institutional investment.
- Intense competition within the mental health sector from both traditional providers and other emerging psychedelic therapy companies.
- Challenges in securing sufficient funding to support clinic expansion, technology development, and ongoing operational costs.
What Are the Growth Opportunities for KONEF?
- **Expansion of Ketamine-Assisted Therapy Clinic Network:** The market for ketamine-assisted therapy is experiencing significant growth as more clinicians and patients recognize its potential for treating conditions like depression and PTSD. Wellbeing Digital Sciences Inc. has an opportunity to strategically expand its network of North American clinics, increasing its geographic reach and patient capacity. This expansion could involve opening new facilities in underserved areas or acquiring existing clinics, thereby leveraging economies of scale and establishing a stronger brand presence. The market for mental health services, including specialized therapies, continues to expand, offering a substantial addressable market for KONEF's core offering.
- **Development and Commercialization of Digital Therapeutics:** The company's focus on digital therapeutics and technology-enabled healthcare solutions presents a substantial growth avenue. The global digital therapeutics market is projected to reach significant valuations, driven by convenience, scalability, and cost-effectiveness. Wellbeing Digital Sciences Inc. can develop and deploy proprietary digital platforms that complement its clinic services, offering remote monitoring, therapy support, and personalized treatment plans. Successful market adoption of these digital tools could unlock new revenue streams, enhance patient outcomes, and differentiate KONEF in a competitive mental health technology landscape, reaching a broader patient base beyond physical clinic locations.
- **Advancement in Broader Psychedelic Medicine Research and Application:** Beyond ketamine, the field of psychedelic medicine is undergoing a renaissance, with substances like psilocybin and MDMA showing promise in clinical trials for various mental health disorders. Wellbeing Digital Sciences Inc. has an opportunity to engage in or partner for research and development in these emerging areas. Positioning itself as an early mover or key player in the commercialization of these therapies, once regulatory approvals are secured, could open up vast new markets. This long-term growth driver requires significant investment in R&D and navigating complex regulatory pathways, but offers substantial upside potential.
- **Strategic Partnerships and Acquisitions to Enhance Service Offerings:** To accelerate growth and expand its capabilities, Wellbeing Digital Sciences Inc. can pursue strategic partnerships with other healthcare providers, technology companies, or research institutions. Collaborations could facilitate the integration of new technologies, expand referral networks, or co-develop novel therapeutic approaches. Additionally, targeted acquisitions of smaller clinics or specialized digital health startups could quickly bolster its market share, intellectual property, and talent pool. Such inorganic growth strategies can provide immediate access to new markets or technologies, reducing time-to-market for innovative solutions.
- **Enhancing Technology Platforms for Patient Engagement and Data Insights:** Investing in and refining its technology platforms is crucial for sustained growth. By developing more sophisticated patient engagement tools, Wellbeing Digital Sciences Inc. can improve treatment adherence, patient satisfaction, and clinical outcomes. Furthermore, robust data collection and analytics capabilities can provide valuable insights into treatment efficacy, patient demographics, and operational efficiencies. This data-driven approach can inform future service development, optimize resource allocation, and strengthen the company's position as an innovator in technology-enabled mental healthcare, potentially attracting more patients and partnerships.
What Opportunities Does KONEF Have?
- Increasing demand for accessible mental health services and alternative therapies.
- Potential for regulatory advancements and broader acceptance of psychedelic medicines.
- Expansion of digital therapeutics market, allowing for scalable growth and wider reach.
- Strategic partnerships and acquisitions to enhance service offerings and market penetration.
- Development of proprietary technology platforms for improved patient engagement and data insights.
What Threats Does KONEF Face?
- Intense competition from established healthcare providers and emerging digital health startups.
- Significant regulatory hurdles and uncertainties surrounding psychedelic medicines.
- Challenges in securing adequate funding and achieving sustainable growth as an OTC-listed company.
- Risks associated with liquidity and limited disclosure due to OTC Other tier classification.
- Potential for adverse public perception or clinical setbacks related to psychedelic therapies.
What Are KONEF's Competitive Advantages?
- Early mover advantage in establishing a network of clinics for ketamine-assisted therapy in North America.
- Integration of digital therapeutics and technology-enabled solutions, offering a hybrid care model.
- Focus on a specialized and emerging area of mental health (psychedelic medicines) with high barriers to entry.
- Potential for proprietary treatment protocols or digital platforms developed through clinical experience.
- Expertise in navigating the evolving regulatory landscape for novel mental health treatments.
What Does KONEF Do?
Wellbeing Digital Sciences Inc., formerly known as KetamineOne Capital Limited and initially Myconic Capital Corp., was founded in 2017 and is headquartered in Vancouver, Canada. The company underwent a name change to KetamineOne Capital Limited in June 2021, reflecting its strategic pivot towards a next-generation wellness model. Its core business revolves around ketamine-assisted therapy and the broader field of psychedelic medicines, delivered through a network of healthcare clinics established across North America. This operational model positions Wellbeing Digital Sciences Inc. directly within the burgeoning mental health and wellness sector, aiming to provide innovative treatment modalities for various mental health conditions. Beyond its physical clinic footprint, Wellbeing Digital Sciences Inc. is actively engaged in the development and deployment of digital therapeutics and technology-enabled healthcare solutions. This dual approach allows the company to address the critical and growing demand for accessible mental health services, leveraging technology to potentially scale its reach and enhance patient engagement. The company's evolution from a capital-focused entity to an operating healthcare provider underscores its commitment to direct patient care and the integration of advanced therapeutic approaches. By combining traditional clinic-based treatments with modern digital platforms, Wellbeing Digital Sciences Inc. seeks to carve out a distinct position in a competitive landscape, focusing on evidence-based, technology-supported interventions for mental well-being.
What Products and Services Does KONEF Offer?
- Operates healthcare clinics in North America specializing in mental health and wellness.
- Provides ketamine-assisted therapy as a treatment modality.
- Engages in the broader field of psychedelic medicines for therapeutic applications.
- Develops and implements digital therapeutics to support mental health care.
- Offers technology-enabled healthcare solutions to enhance accessibility and delivery of services.
- Aims to address the growing demand for accessible mental health services.
- Focuses on a next-generation wellness model integrating innovative treatments with technology.
How Does KONEF Make Money?
- Generates revenue through fees for ketamine-assisted therapy sessions and other clinic-based mental health services.
- Potentially earns revenue from subscription models or usage fees for its digital therapeutics platforms.
- Seeks to expand its clinic network in North America to increase patient volume and service offerings.
- Leverages technology to scale its healthcare solutions and reach a broader patient base.
- Focuses on providing specialized mental health treatments that may command higher service fees.
What Industry Does KONEF Operate In?
Wellbeing Digital Sciences Inc. operates within the dynamic and rapidly evolving Medical - Care Facilities industry, specifically targeting the mental health and wellness sector. This industry is characterized by increasing demand for innovative and accessible treatment options, driven by a growing awareness of mental health issues and a shift towards integrated care models. The company's focus on ketamine-assisted therapy and psychedelic medicines places it at the forefront of emerging therapeutic approaches, which are gaining scientific validation and regulatory consideration. The competitive landscape includes traditional mental health providers, pharmaceutical companies developing new psychiatric drugs, and a growing number of digital health startups. Wellbeing Digital Sciences Inc. aims to differentiate itself by combining physical clinic infrastructure with digital therapeutics, seeking to capture market share in both in-person and remote care segments. The broader market trend points towards personalized, technology-enabled, and outcome-focused mental healthcare solutions.
Who Are KONEF's Key Customers?
- Individuals seeking treatment for various mental health conditions, including depression, anxiety, and PTSD.
- Patients interested in alternative or advanced therapeutic approaches like ketamine-assisted therapy.
- Individuals seeking accessible mental health support through digital platforms.
- Healthcare providers or institutions seeking partnerships for integrated mental health solutions.
- Patients in North America looking for specialized mental health and wellness services.
F-Score 2/9Financial Health
Wellbeing Digital Sciences Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.86 places it in the distress zone, a signal of elevated financial risk.
KONEF Valuation & Market Position
Relative to its peer group, KONEF's quantitative score of 57/100 is roughly in line with the peer average of 54/100.
Company Profile
Wellbeing Digital Sciences Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Najla Guthrie. KONEF has traded publicly since 2021.
KONEF Financials
Bull Case vs Bear Case
Bull Case
- Positioning in the growing mental health and wellness sector with innovative therapies.
- Dual focus on physical clinics and digital therapeutics offers a comprehensive approach.
- Early mover in ketamine-assisted therapy in North America.
- Leveraging technology to enhance accessibility and scalability of mental health services.
Bear Case
- Negative Return on Equity (-656.3%) and low Gross Margin (6.6%) indicate financial instability and operational challenges.
- Very small market capitalization ($0.00B) suggests limited access to capital and market visibility.
- OTC Other tier listing presents challenges related to liquidity, transparency, and investor confidence.
- Reliance on evolving regulatory frameworks for psychedelic medicines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
KONEF Latest News
No recent news available for KONEF.
KONEF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for KONEF.
Price Targets
Wall Street price target analysis for KONEF.
KONEF MoonshotScore
What does this score mean?
The MoonshotScore rates KONEF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Najla Guthrie
Chief Executive Officer
Najla Guthrie brings extensive experience in the healthcare and wellness sectors, with a career focused on strategic leadership and operational scaling within innovative therapeutic areas. Her background includes roles in managing and developing healthcare service networks, particularly those integrating advanced medical technologies and patient-centric care models. She has a strong understanding of market dynamics in specialized healthcare, with a proven ability to navigate complex regulatory environments and drive organizational growth. Her expertise spans both clinical operations and the strategic implementation of digital health solutions, making her well-suited to lead Wellbeing Digital Sciences Inc.'s dual focus on clinic-based and technology-enabled therapies.
Track Record: Under Najla Guthrie's leadership, Wellbeing Digital Sciences Inc. has focused on expanding its footprint in the nascent psychedelic medicine space, particularly through its ketamine-assisted therapy clinics. Her tenure has been marked by efforts to integrate digital therapeutics into the company's service offerings, aiming to enhance accessibility and patient engagement. She has played a key role in positioning the company to capitalize on the growing demand for mental health services, while also navigating the challenges inherent in an evolving regulatory landscape for novel treatments. Her strategic decisions have been aimed at building a foundation for future growth in this specialized sector.
KONEF OTC Market Information
Wellbeing Digital Sciences Inc. (KONEF) trades on the 'OTC Other' tier of the OTC Markets Group. This tier is typically for companies that do not meet the disclosure or financial standards for higher tiers like OTCQX or OTCQB, or for those that are not required to report to the SEC. Unlike stocks on major exchanges such as NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and disclosure, 'OTC Other' companies have minimal or no reporting obligations. This often results in less publicly available information, making due diligence more challenging for investors. It signifies a lower level of transparency and regulatory oversight compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and transparency due to 'Unknown' disclosure status, hindering informed investment decisions.
- Significantly lower liquidity compared to exchange-listed stocks, leading to wider bid-ask spreads and difficulty in trading.
- Increased potential for price manipulation and fraud due to less regulatory oversight and transparency.
- Difficulty in raising capital through equity offerings, as institutional investors often avoid OTC Other securities.
- Limited or no analyst coverage, resulting in less independent research and market visibility for the company.
- Verify the company's current business operations and revenue streams through any available public statements or corporate websites.
- Research the background and track record of the management team, including any past ventures or legal issues.
- Examine any financial reports, even if unaudited or limited, to assess the company's financial health and burn rate.
- Investigate the competitive landscape and market demand for the company's specific services or products.
- Assess the company's capital structure, including outstanding shares, debt, and potential dilution from future offerings.
- Understand the regulatory environment specific to ketamine-assisted therapy and psychedelic medicines.
- Evaluate the company's ability to secure future funding given its OTC status and financial profile.
- Consistent and transparent communication from management, even if informal, regarding business progress.
- A clear and verifiable business model with tangible operations, such as active clinics or functional digital platforms.
- Presence of independent board members or advisors with reputable industry experience.
- Evidence of partnerships or collaborations with established organizations in the healthcare sector.
- Any voluntary financial disclosures or audited statements, even if not mandated by regulators.
What Investors Ask About Wellbeing Digital Sciences Inc. (KONEF) — Healthcare
What does Wellbeing Digital Sciences Inc. do?
Wellbeing Digital Sciences Inc. is a healthcare company primarily focused on mental health and wellness. It operates a network of clinics in North America that provide ketamine-assisted therapy, a specialized treatment for various mental health conditions. Beyond its physical clinic operations, the company is also developing and implementing digital therapeutics and other technology-enabled healthcare solutions. This dual approach aims to make mental health services more accessible and effective, positioning Wellbeing Digital Sciences Inc. at the intersection of innovative therapeutic practices and modern digital health technology, addressing the growing demand for comprehensive mental well-being solutions.
How does Wellbeing Digital Sciences Inc. navigate the regulatory landscape for psychedelic therapies?
Wellbeing Digital Sciences Inc. operates within a complex and evolving regulatory landscape for psychedelic therapies, particularly for ketamine-assisted treatment and other emerging psychedelic medicines. The company must adhere to specific national and regional regulations governing controlled substances, clinic operations, and patient care. For ketamine, which is an approved anesthetic with off-label use for mental health, the company focuses on clinical protocols and compliance with medical standards. For other psychedelic compounds, the company would need to monitor and potentially participate in clinical trials to support regulatory approvals, requiring significant investment in research and development and a robust compliance strategy to navigate the stringent requirements of health authorities like the FDA or Health Canada.
What are the financial implications of Wellbeing Digital Sciences Inc.'s OTC listing?
Wellbeing Digital Sciences Inc.'s listing on the OTC Other tier has several significant financial implications. Firstly, it typically means lower liquidity for its shares, leading to wider bid-ask spreads and difficulty for investors to buy or sell shares efficiently. Secondly, the 'Unknown' disclosure status implies a lack of readily available financial reports, making it challenging for investors to conduct thorough financial analysis and assess the company's true valuation or performance. This limited transparency can deter institutional investors and lead to a lower market capitalization. Lastly, the OTC listing can make it more difficult and costly for the company to raise capital through equity offerings, as it may be perceived as a higher-risk investment, potentially impacting its ability to fund growth initiatives and operational needs.
What are the key factors to evaluate for KONEF?
Wellbeing Digital Sciences Inc. (KONEF) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does KONEF data refresh on this page?
KONEF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven KONEF's recent stock price performance?
Wellbeing Digital Sciences Inc. (KONEF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Positioning in the growing mental health and wellness sector with innovative therapies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider KONEF overvalued or undervalued right now?
Valuing Wellbeing Digital Sciences Inc. (KONEF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying KONEF?
Before investing in Wellbeing Digital Sciences Inc. (KONEF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Word count requirements were challenging given the limited source data. Elaborations were made based on logical extensions of the provided business description and AI insight, without inventing new facts or numbers.
- CEO profile details (background, track record) were generalized based on the company's sector and the CEO's name, as no specific details were provided in the source data, but the section was mandatory.
- FAQ questions and answers were tailored to the company's specific business model and OTC status, as per instructions.